English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe Korea Research Institute of Standards and Science (KRISS) has unveiled a new principle for controlling the microenvironment of biological tissues to promote wound healing and regeneration.
Tag: Scleroderma
Targeting TAK1 protein to treat systemic sclerosis
Systemic sclerosis is the scaring of multiple organs within the body resulting in difficulty in functioning for these organs. The disease can become deadly if the organ scaring isn’t treated properly. Researchers at the University of Michigan Health System have identified a protein in the disease that may be a new target for treatment.
Molecule known to slow inflammation linked to scleroderma, could be treatment target
A molecule that was until recently known as a brake on inflammation has now been implicated in fibrosis in scleroderma patients.
How the western diet and gut bacteria can lead to scarring, vessel damage in scleroderma
A substance produced by gut microorganisms can lead to scarring and blood vessel damage in patients with scleroderma, a new study suggests. Researchers say they will examine whether drugs or food products, like virgin olive oil, can block the formation of the compound in the gut to treat fibrosis.
Drugs showing promise in cancer trials reduce scarring for scleroderma, study shows
Epigenetic drugs that have shown promise in cancer trials significantly reduce scarring in the cells of patients with scleroderma, a new study shows. Results reveal that drugs that inhibit BRD4, known to play a role in cancer, also affect fibrosis in scleroderma. Researchers tested BRD4 inhibitors on the skin fibroblasts of scleroderma patients and in mouse models of skin fibrosis, finding that the treatment stopped scarring in both human-derived cells and in animals.
Patients with rare scleroderma have deadlier organ damage, despite getting standard treatment
Patients with a rare form of scleroderma that causes more skin thickening have a greater chance of dying from related heart, lung and kidney problems, a new study found. This occurs despite the patient population taking drugs used to treat most people with scleroderma. Researchers say it is an opportunity for more targeted drug development.
Potential biomarker found for lung disease in scleroderma patients
Researchers have discovered a protein that may predict disease severity for scleroderma-associated interstitial lung disease, the leading cause of death for patients with the rare autoimmune condition. Higher circulating levels of the CTRP9 were associated with more severe lung disease, while low levels were associated with preserved function.
Positively Battling Scleroderma
Scleroderma has taken both of Lovette Twyman Russell’s lungs and the tips of three of her fingers, but not one ounce of her joy in life. For the 58-year-old former triathlete, getting the right treatment for this rare autoimmune disease – which causes abnormal growth of connective tissue and can permanently damage the joints, skin, cartilage and internal organs – has made all the difference.
Online mental health intervention significantly helps the isolated, immunosuppressed during pandemic
People with the rare autoimmune disease scleroderma, who likely experience more serious isolation during a global pandemic, saw their anxiety and depression improve after receiving online mental health intervention through an international study. Researchers say the support program could be extended to many vulnerable patient populations moving forward.
Repurposing Tocilizumab in Scleroderma Patients May Prevent Early Lung Disease
A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis.
March Special Issue of The American Journal of Gastroenterology Focuses on Women’s Health in Gastroenterology and Hepatology
The March issue of The American Journal of Gastroenterology features new clinical research involving sex and gender, including effects of GI and liver conditions on pregnancy, gender disparities in diet and nutrition, Barrett’s esophagus incidence in women with scleroderma, factors influencing whether women pursue advanced endoscopy careers, endoscopy-related musculoskeletal injuries, sex hormone association with increased prevalence of certain types of cancer, and more.
National Research Effort Discovers Relationship Between Inflammation, Metabolism and Scleroderma Scarring
Study finds NAD+ break down leads to multi organ scarring, providing now a previously undiscovered pathogenic role of the enzyme CD38 in disease scarring.
Protein Linked to Progressive Lung Scarring in Scleroderma Patients
Osteopontin is discovered as the culprit behind these patients’ main cause of death. However, a repurposed immunosuppressive drug may combat the pro-inflammatory protein.
Prominent Rheumatologist to Create Scleroderma Program at Kao Institute
Nationally recognized rheumatology expert Francesco Boin, MD, has been appointed director of the division of Rheumatology and director of the new Scleroderma Program at Cedars-Sinai. Boin is an accomplished and widely published investigator of autoimmune diseases, with a reputation for clinical excellence and a multidisciplinary approach to patient care.
Cedars-Sinai Receives $20M to Create Kao Autoimmunity Institute
Cedars-Sinai today announced a $20 million gift from Dr. and Mrs. Min H. Kao and the Kao Family Foundation to create the Kao Autoimmunity Institute to advance research and treatment of rheumatologic diseases. The gift also will establish the Scleroderma Program within the institute to provide interdisciplinary and integrated care for scleroderma patients and to support research, outreach, training and education to help those with the disease.